PTGS2 and colonic neoplasm: Similar to honokiol, traditional non-steroidal anti-inflammatory drugs, such as sulindac, inhibit COX-2 expression and resulting in reduced Wnt-signaling by induced β-catenin degradation, as has been shown in colon cancer [39].